TheralinkTheralink

  • Theralink
    • The Theralink platform
    • The Theralink Assay
    • Request RPPA Analyte List
    • RPPA Clinical Publications
    • RPPA Research Publications
    • RPPA Technical Publications
  • About
    • Overview
    • Oncologists
    • Mission Statement
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
  • News & Media
    • Press Releases
    • Media & Articles
    • Theralink Blog
  • Biopharmas
    • Overview
    • Explore Technology
    • Explore Targets
    • Explore Pathways
    • Request Pathway Quote
    • Conference Abstracts
    • FAQ
  • Investor Relations
    • Market Opportunity
    • Investor Relations Email Alerts
    • Company Information
    • Management Team
    • Medical Advisory Board
    • Scientific Advisory Board
    • Board of Directors
    • Contact
    • Investors Relations FAQ
  • Contacts

Annual Reports

Theralink   →  Annual Reports

Annual Reports

FINANCIAL INFORMATION

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
DATE From DESCRIPTION DOCS XBRL
01/13/22 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
12/30/21 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
09/27/21 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
03/25/20 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
04/01/19 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
05/31/18 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
04/02/18 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
04/17/17 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
04/03/17 NT 10-K/A Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: [Amend]
03/31/17 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
  • << Previous
  • 1
  • 2
  • 3

SEC Filings

  • All SEC Filings
  • Annual Reports
  • Quarterly Reports
  • Section 16 Filings
Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Menu

  • About
  • Investors
  • Contact
  • Privacy Policy

OUR SERVICES

  • Biopharmas
  • Oncologists
  • Media Room

Press Releases

  • Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
  • Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
  • Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
Copyright © 2022 Theralink. All rights reserved.